World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult - A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 31, Issue 9, 2012, Pages 913-933

  Fang, James C ^a   Demarco, Teresa ^b   Givertz, Michael M ^c   Borlaug, Barry A ^d   Lewis, Gregory D ^e   Rame, J Eduardo ^f   Gomberg Maitland, Mardi ^g   Murali, Srinivas ^h   Frantz, Robert P ^d   McGlothlin, Dana ^b   Horn, Evelyn M ⁱ   Benza, Raymond L ^h  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MAYO CLINIC   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h ALLEGHENY GENERAL HOSPITAL   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

heart failure; heart transplant; left heart disease; left ventricular assist device; pulmonary hypertension; right heart failure

Indexed keywords

ADENOSINE; BOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENOXIMONE; GLYCERYL TRINITRATE; HYDRALAZINE; MILRINONE; NESIRITIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; RIOCIGUAT; SILDENAFIL; SITAXSENTAN; TEZOSENTAN;

ADULT DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE INDUCED PULMONARY HYPERTENSION; HEART CATHETERIZATION; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; INVASIVE PROCEDURE; LABORATORY TEST; LEFT HEART DISEASE; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; MEDICAL HISTORY; MEDICAL SOCIETY; METHEMOGLOBINEMIA; MITRAL VALVE DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PEER REVIEW; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIOCARDIOGRAPHY; REDUCED LEFT VENTRICLE EJECTION FRACTION; SYNCOPE; TISSUE DOPPLER IMAGING; VASODILATATION;

HEART DISEASES; HEART-ASSIST DEVICES; HUMANS; HYPERTENSION, PULMONARY; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE STENOSIS; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ENDOTHELIN; VASODILATOR AGENTS;

EID: 84864924644     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2012.06.002     Document Type: Article

References (187)

1. D.B. Badesch, H.C. Champion, M.A. Sanchez Diagnosis and assessment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S55 S66
2. E.D. Flores, R.A. Lange, L.D. Hillis Relation of mean pulmonary arterial wedge pressure and left ventricular end-diastolic pressure Am J Cardiol 66 1990 1532 1533
3. G. Kovacs, A. Berghold, S. Scheidl, H. Olschewski Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review Eur Respir J 34 2009 888 894
4. R.J. Oudiz Pulmonary hypertension associated with left-sided heart disease Clin Chest Med 28 2007 233 241 x
5. G. Simonneau, I.M. Robbins, M. Beghetti Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 2009 S43 S54
6. S. Ghio Pulmonary hypertension in advanced heart failure Herz 30 2005 311 317
7. J. Butler, D.B. Chomsky, J.R. Wilson Pulmonary hypertension and exercise intolerance in patients with heart failure J Am Coll Cardiol 34 1999 1802 1806
8. K.K. Khush, G. Tasissa, J. Butler, D. McGlothlin, T. De Marco Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database Am Heart J 157 2009 1026 1034
9. S. Ghio, A. Gavazzi, C. Campana Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure J Am Coll Cardiol 37 2001 183 188
10. C.S. Lam, B.A. Borlaug, G.C. Kane, F.T. Enders, R.J. Rodeheffer, M.M. Redfield Age-associated increases in pulmonary artery systolic pressure in the general population Circulation 119 2009 2663 2670
11. B.A. Borlaug, R.A. Nishimura, P. Sorajja, C.S. Lam, M.M. Redfield Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction Circ Heart Fail 3 2010 588 595
12. G. Lewis, R. Murphy, R. Shah Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes Circ Heart Fail 4 2011 276 285
13. R.J. Tedford, P.M. Hassoun, S.C. Mathai Pulmonary capillary wedge pressure augments right ventricular pulsatile loading Circulation 125 2012 289 297
14. D.L. Moraes, W.S. Colucci, M.M. Givertz Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management Circulation 102 2000 1718 1723
15. F. Haddad, R. Doyle, D.J. Murphy, S.A. Hunt Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure Circulation 117 2008 1717 1731
16. F. Haddad, S.A. Hunt, D.N. Rosenthal, D.J. Murphy Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle Circulation 117 2008 1436 1448
17. G.G. Pietra, F. Capron, S. Stewart Pathologic assessment of vasculopathies in pulmonary hypertension J Am Coll Cardiol 43 2004 25 32S
18. M. Rabinovitch PPARgamma and the pathobiology of pulmonary arterial hypertension Adv Exp Med Biol 661 2010 447 458
19. M. Ontkean, R. Gay, B. Greenberg Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure Circ Res 69 1991 1088 1096
20. C.J. Cooper, F.W. Jevnikar, T. Walsh, J. Dickinson, A. Mouhaffel, A.P. Selwyn The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure Am J Cardiol 82 1998 609 614
21. V. Melenovsky, H. Al-Hiti, L. Kazdova Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil J Am Coll Cardiol 54 2009 595 600
22. N. Galie, A. Manes, A. Branzi Prostanoids for pulmonary arterial hypertension Am J Respir Med 2 2003 123 137
23. G. Montalescot, G. Drobinski, P. Meurin Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure Am J Cardiol 82 1998 749 755
24. R.M. Califf, K.F. Adams, W.J. McKenna A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) Am Heart J 134 1997 44 54
25. F. Kerbaul, S. Brimioulle, B. Rondelet, C. Dewachter, I. Hubloue, R. Naeije How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension Am J Respir Crit Care Med 175 2007 846 850
26. R.J. Cody, G.J. Haas, P.F. Binkley, Q. Capers, R. Kelley Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure Circulation 85 1992 504 509
27. T. Tsutamoto, A. Wada, Y. Maeda, T. Adachi, M. Kinoshita Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure J Am Coll Cardiol 23 1994 1427 1433
28. M. Givertz, W. Colucci, T. LeJemtel Investigators BotS Acute endothlin A receptor blockade cause selective pulmonary vasodilation in patients with chronic heart failure Circulation 101 2000 2922 2927
29. H. Ooi, W.S. Colucci, M.M. Givertz Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan Circulation 106 2002 1618 1621
30. Y. Sun, F.J. Ramires, K.T. Weber Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion Cardiovasc Res 35 1997 138 147
31. S.L. Archer, E.K. Weir, M.R. Wilkins Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies Circulation 121 2010 2045 2066
32. R.D. Machado, M.W. Pauciulo, J.R. Thomson BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension Am J Hum Genet 68 2001 92 102
33. J. Nagendran, S.L. Archer, D. Soliman Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 2007 238 248
34. M.E. Fawzy, W. Hassan, M. Stefadouros, M. Moursi, F. El Shaer, M.A. Chaudhary Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy J Heart Valve Dis 13 2004 942 947 discussion 947-8
35. E. Braunwald, N.S. Braunwald, J. Ross Jr, A.G. Morrow Effects of Mitral-Valve Replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension N Engl J Med 273 1965 509 514
36. R. Reeve, A. Selzer, R.W. Popper, R.F. Leeds, F. Gerbode Reversibility of pulmonary hypertension following cardiac surgery Circulation 33 1966 I107 I114
37. H.J. Semler, J.T. Shepherd, E.H. Wood The role of vessel tone in maintaining pulmonary vascular resistance in patients with mitral stenosis Circulation 19 1959 386 394
38. D. Alexopoulos, C. Lazzam, S. Borrico, L. Fiedler, J.A. Ambrose Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension J Am Coll Cardiol 14 1989 319 322
39. E. Schwammenthal, Z. Vered, O. Agranat, E. Kaplinsky, B. Rabinowitz, M.S. Feinberg Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study Circulation 102 2000 2378 2384
40. H.K. Kim, Y.J. Kim, S.J. Hwang Hemodynamic and prognostic implications of net atrioventricular compliance in patients with mitral stenosis J Am Soc Echocardiogr 21 2008 482 486
41. A. Barbieri, F. Bursi, F. Grigioni Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: A Multicenter Long-term International Study Eur Heart J 32 2011 751 759
42. R.A. Cesnjevar, R. Feyrer, F. Walther, F.O. Mahmoud, Y. Lindemann, J. von der Emde High-risk mitral valve replacement in severe pulmonary hypertension - 30 years experience Eur J Cardiothorac Surg 13 1998 344 351 discussion 351-2
43. P.G. Cevese, V. Gallucci, C. Valfre, A. Giacomin, A. Mazzucco, D. Casarotto Pulmonary hypertension in mitral valve surgery J Cardiovasc Surg (Torino) 21 1980 7 10
44. J.J. Vincens, D. Temizer, J.R. Post, L.H. Edmunds Jr, H.C. Herrmann Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension Circulation 92 1995 II137 II142
45. C. Ward, B.W. Hancock Extreme pulmonary hypertension caused by mitral valve disease Natural history and results of surgery Br Heart J 37 1975 74 78
46. P. Montant, F. Chenot, A. Robert Long-term survival in asymptomatic patients with severe degenerative mitral regurgitation: a propensity score-based comparison between an early surgical strategy and a conservative treatment approach J Thorac Cardiovasc Surg 138 2009 1339 1348
47. R.O. Bonow, B.A. Carabello, K. Chatterjee ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J Am Coll Cardiol 48 2006 e1 e148
48. D.K. Tempe, S. Hasija, V. Datt Evaluation and comparison of early hemodynamic changes after elective mitral valve replacement in patients with severe and mild pulmonary arterial hypertension J Cardiothorac Vasc Anesth 23 2009 298 305
49. B.D. Foltz, E.A. Hessel 2nd, T.D. Ivey The early course of pulmonary artery hypertension in patients undergoing mitral valve replacement with cardioplegic arrest J Thorac Cardiovasc Surg 88 1984 238 247
50. T.K. Kaul, W.H. Bain, J.V. Jones Mitral valve replacement in the presence of severe pulmonary hypertension Thorax 31 1976 332 336
51. M. Li, K.R. Chiou, A. Bugayenko, K. Irani, D.A. Kass Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion Circ Res 97 2005 587 595
52. J. Magne, M. Senechal, P. Mathieu, J.G. Dumesnil, F. Dagenais, P. Pibarot Restrictive annuloplasty for ischemic mitral regurgitation may induce functional mitral stenosis J Am Coll Cardiol 51 2008 1692 1701
53. A. Costard-Jackle, M.B. Fowler Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group J Am Coll Cardiol 19 1992 48 54
54. D. Aronson, A. Eitan, R. Dragu, A.J. Burger The relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure Circ Heart Fail 4 2011 644 650
55. S.V. Abramson, J.F. Burke, J.J. Kelly Jr Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy Ann Intern Med 116 1992 888 895
56. T.P. Cappola, G.M. Felker, W.H. Kao, J.M. Hare, K.L. Baughman, E.K. Kasper Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk Circulation 105 2002 1663 1668
57. J.A. Franciosa, B.J. Baker, L. Seth Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure Am Heart J 110 1985 807 813
58. G.D. Lewis, R.V. Shah, P.P. Pappagianopolas, D.M. Systrom, M.J. Semigran Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone Circ Heart Fail 1 2008 227 233
59. R. Arena, J. Myers, J. Abella Development of a ventilatory classification system in patients with heart failure Circulation 115 2007 2410 2417
60. M. Enriquez-Sarano, A. Rossi, J.B. Seward, K.R. Bailey, A.J. Tajik Determinants of pulmonary hypertension in left ventricular dysfunction J Am Coll Cardiol 29 1997 153 159
61. G. Tumminello, P. Lancellotti, M. Lempereur, V. D'Orio, L.A. Pierard Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure Eur Heart J 28 2007 569 574
62. T.G. Di Salvo, M. Mathier, M.J. Semigran, G.W. Dec Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure J Am Coll Cardiol 25 1995 1143 1153
63. D. Verhaert, W. Mullens, A. Borowski Right ventricular response to intensive medical therapy in advanced decompensated heart failure Circ Heart Fail 3 2010 340 346
64. K.W. Erickson, M.R. Costanzo-Nordin, E.J. O'Sullivan Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation J Heart Transplant 9 1990 526 537
65. J.K. Kirklin, D.C. Naftel, J.W. Kirklin, E.H. Blackstone, C. White-Williams, R.C. Bourge Pulmonary vascular resistance and the risk of heart transplantation J Heart Transplant 7 1988 331 336
66. M.J. Semigran, B.A. Cockrill, R. Kacmarek Hemodynamic effects of inhaled nitric oxide in heart failure J Am Coll Cardiol 24 1994 982 988
67. M.R. Mehra, J. Kobashigawa, R. Starling Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006 J Heart Lung Transplant 25 2006 1024 1042
68. J. Kjaergaard, D. Akkan, K.K. Iversen Prognostic importance of pulmonary hypertension in patients with heart failure Am J Cardiol 99 2007 1146 1150
69. M. Klapholz, M. Maurer, A.M. Lowe Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry J Am Coll Cardiol 43 2004 1432 1438
70. C.C. Leung, V. Moondra, E. Catherwood, B.W. Andrus Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction Am J Cardiol 106 2010 284 286
71. B.A. Borlaug, W.J. Paulus Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 2011 670 679
72. B.P. Shapiro, M.D. McGoon, M.M. Redfield Unexplained pulmonary hypertension in elderly patients Chest 131 2007 94 100
73. J.L. Bouchard, G.P. Aurigemma, J.C. Hill, C.A. Ennis, D.A. Tighe Usefulness of the pulmonary arterial systolic pressure to predict pulmonary arterial wedge pressure in patients with normal left ventricular systolic function Am J Cardiol 101 2008 1673 1676
74. B.A. Borlaug Discerning pulmonary venous from pulmonary arterial hypertension without the help of a catheter Circ Heart Fail 4 2011 235 237
75. T. Thenappan, S.J. Shah, M. Gomberg-Maitland Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction Circ Heart Fail 4 2011 257 265
76. J.S. Gibbs, J. Keegan, C. Wright, K.M. Fox, P.A. Poole-Wilson Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure J Am Coll Cardiol 15 1990 52 61
77. R.C. Bourge, W.T. Abraham, P.B. Adamson Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study J Am Coll Cardiol 51 2008 1073 1079
78. J.T. Reeves, R.E. Moon, R.F. Grover, B.M. Groves Increased wedge pressure facilitates decreased lung vascular resistance during upright exercise Chest 93 1988 97S 99S
79. J.J. Tolle, A.B. Waxman, T.L. Van Horn, P.P. Pappagianopoulos, D.M. Systrom Exercise-induced pulmonary arterial hypertension Circulation 118 2008 2183 2189
80. G.D. Lewis, J. Lachmann, J. Camuso Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure Circulation 115 2007 59 66
81. P.V. Ennezat, Y. Lefetz, S. Marechaux Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest J Card Fail 14 2008 475 480
82. M.M. Hoeper, J.A. Barbera, R.N. Channick Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension J Am Coll Cardiol 54 2009 S85 S96
83. I.M. Robbins, J.H. Newman, R.F. Johnson Association of the metabolic syndrome with pulmonary venous hypertension Chest 136 2009 31 36
84. N. Nagaya, T. Nishikimi, M. Uematsu Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension Circulation 102 2000 865 870
85. J.W. Ha, D. Choi, S. Park Determinants of exercise-induced pulmonary hypertension in patients with normal left ventricular ejection fraction Heart 95 2009 490 494
86. P.J. Currie, J.B. Seward, K.L. Chan Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients J Am Coll Cardiol 6 1985 750 756
87. M.R. Fisher, P.R. Forfia, E. Chamera Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension Am J Respir Crit Care Med 179 2009 615 621
88. E.K. Louie, S. Rich, B.H. Brundage Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension J Am Coll Cardiol 8 1986 1298 1306
89. E. Bossone, T.H. Duong-Wagner, G. Paciocco Echocardiographic features of primary pulmonary hypertension J Am Soc Echocardiogr 12 1999 655 662
90. C.T. Gan, J.W. Lankhaar, J.T. Marcus Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension Am J Physiol Heart Circ Physiol 290 2006 H1528 H1533
91. H.J. Willens, J.A. Chirinos, O. Gomez-Marin Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography J Am Soc Echocardiogr 21 2008 715 719
92. V.V. McLaughlin, S.L. Archer, D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 53 2009 1573 1619
93. M.M. Redfield, S.J. Jacobsen, J.C. Burnett Jr, D.W. Mahoney, K.R. Bailey, R.J. Rodeheffer Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA 289 2003 194 202
94. A.E. Abbas, F.D. Fortuin, N.B. Schiller, C.P. Appleton, C.A. Moreno, S.J. Lester A simple method for noninvasive estimation of pulmonary vascular resistance J Am Coll Cardiol 41 2003 1021 1027
95. N. Rajagopalan, M.A. Simon, M.S. Suffoletto Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension Echocardiography 26 2009 489 494
96. J.S. Arkles, A.R. Opotowsky, J. Ojeda Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension Am J Respir Crit Care Med 183 2011 268 276
97. D.P. Leong, C.G. De Pasquale, J.B. Selvanayagam Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging JACC Cardiovasc Imaging 3 2010 409 420
98. A. Garcia-Alvarez, L. Fernandez-Friera, J.G. Mirelis Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance Eur Heart J 32 2011 2438 2445
99. R. Benza, R. Biederman, S. Murali, H. Gupta Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension J Am Coll Cardiol 52 2008 1683 1692
100. R.J. Lederman Cardiovascular interventional magnetic resonance imaging Circulation 112 2005 3009 3017
101. T. Kuehne, S. Yilmaz, P. Steendijk Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension Circulation 110 2004 2010 2016
102. A.M. Maceira, J. Joshi, S.K. Prasad Cardiovascular magnetic resonance in cardiac amyloidosis Circulation 111 2005 186 193
103. G. Pons-Llado, F. Carreras, X. Borras, J. Palmer, J. Llauger, A. Bayes de Luna Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging Am J Cardiol 79 1997 1651 1656
104. E. Belloni, F. De Cobelli, A. Esposito MRI of cardiomyopathy AJR Am J Roentgenol 191 2008 1702 1710
105. V.K. Rathi, M. Doyle, J. Yamrozik Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: a practical approach J Cardiovasc Magn Reson 10 2008 36
106. C.A. Bush, J.M. Stang, C.F. Wooley, J.W. Kilman Occult constrictive pericardial disease Diagnosis by rapid volume expansion and correction by pericardiectomy Circulation 56 1977 924 930
107. I. Pacold, M.H. Hwang, R.T. Palac, P.J. Scanlon, H.S. Loeb The effects of rapid volume expansion on the right and left cardiac filling pressures after coronary artery bypass surgery Chest 93 1988 1144 1147
108. B.A. Boilson, J.A. Schirger, B.A. Borlaug Caveat medicus! Pulmonary hypertension in the elderly: a word of caution Eur J Heart Fail 12 2010 89 93
109. E. Loh, J.S. Stamler, J.M. Hare, J. Loscalzo, W.S. Colucci Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction Circulation 90 1994 2780 2785
110. E.K. Louie, S.S. Lin, S.I. Reynertson, B.H. Brundage, S. Levitsky, S. Rich Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fraction Circulation 92 1995 819 824
111. L.W. Stevenson, R.C. Brunken, G. Belil D Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure J Am Coll Cardiol 15 1990 174 180
112. L.W. Stevenson, K.A. Dracup, J.H. Tillisch Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation Am J Cardiol 63 1989 461 464
113. S. Klotz, M.C. Deng, D. Hanafy Reversible pulmonary hypertension in heart transplant candidates - pretransplant evaluation and outcome after orthotopic heart transplantation Eur J Heart Fail 5 2003 645 653
114. J. Martin, M.P. Siegenthaler, O. Friesewinkel Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study Eur J Cardiothorac Surg 25 2004 971 977
115. J.F. Malouf, M. Enriquez-Sarano, P.A. Pellikka Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications J Am Coll Cardiol 40 2002 789 795
116. S.J. Bhatia, J.M. Kirshenbaum, R.J. Shemin Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation Circulation 76 1987 819 826
117. B. Lindelow, B. Andersson, F. Waagstein, C.H. Bergh High and low pulmonary vascular resistance in heart transplant candidates A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate Eur Heart J 20 1999 148 156
118. E.A. Bocchi, F. Bacal, J.O. Auler Junior, M.J. Carmone, G. Bellotti, F. Pileggi Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure Am J Cardiol 74 1994 70 72
119. M. Humbert, S. Ma^itre, F. Capron Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis Am J Respir Crit Care Med 157 1998 1681 1685
120. S.M. Palmer, L.J. Robinson, A. Wang, J.R. Gossage, T. Bashore, V.F. Tapson Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease Chest 113 1998 237 240
121. I.R. Preston, J.R. Klinger, J. Houtchens, D. Nelson, S. Mehta, N.S. Hill Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome Chest 121 2002 656 659
122. A. Gavazzi, S. Ghio, L. Scelsi Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension Am Heart J 145 2003 310 316
123. W. Mullens, Z. Abrahams, G.S. Francis Sodium nitroprusside for advanced low-output heart failure J Am Coll Cardiol 52 2008 200 207
124. S. Murali, B.F. Uretsky, P.S. Reddy, T.R. Tokarczyk, A.R. Betschart Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents Am Heart J 122 1991 1375 1381
125. C. Frostell, M.D. Fratacci, J.C. Wain, R. Jones, W.M. Zapol Inhaled nitric oxide A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction Circulation 83 1991 2038 2047
126. C.J. Cooper, M.J. Landzberg, T.J. Anderson Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans Circulation 93 1996 266 271
127. F. Ichinose, J.D. Roberts Jr, W.M. Zapol Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential Circulation 109 2004 3106 3111
128. N. Kieler-Jensen, S.E. Ricksten, O. Stenqvist Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance J Heart Lung Transplant 13 1994 366 375
129. D.T. Balzer, H.W. Kort, R.W. Day Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group Circulation 106 2002 I76 I81
130. A. Sablotzki, T. Hentschel, E. Gruenig Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance Eur J Cardiothorac Surg 22 2002 746 752
131. O.I. Miller, S.F. Tang, A. Keech, D.S. Celermajer Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide Lancet 346 1995 51 52
132. A.D. Michaels, K. Chatterjee, T. De Marco Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension J Card Fail 11 2005 425 431
133. K.M. O'Dell, J.S. Kalus, S. Kucukarslan, B. Czerska Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure Am J Health Syst Pharm 62 2005 606 609
134. J.D. Sackner-Bernstein, H.A. Skopicki, K.D. Aaronson Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 2005 1487 1491
135. C.M. O'Connor, R.C. Starling, A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
136. B. Stanek, B. Sturm, B. Frey Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine J Heart Lung Transplant 18 1999 358 366
137. M. Yanagisawa, H. Kurihara, S. Kimura A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415
138. K. Ponicke, M. Vogelsang, M. Heinroth Endothelin receptors in the failing and nonfailing human heart Circulation 97 1998 744 751
139. O. Zolk, J. Quattek, G. Sitzler Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure Circulation 99 1999 2118 2123
140. K. Yamamoto, T. Masuyama, Y. Sakata Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts Cardiovasc Res 47 2000 274 283
141. K. Yamamoto, T. Masuyama, Y. Sakata, N. Nishikawa, T. Mano, M. Hori Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart J Hypertens 20 2002 753 761
142. L.E. Spieker, V. Mitrovic, G. Noll et al. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure ET 003 Investigators J Am Coll Cardiol 35 2000 1745 1752
143. I. Anand, J. McMurray, J.N. Cohn Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 347 354
144. A.P. Coletta, J.G. Cleland Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME Eur J Heart Fail 3 2001 747 750
145. E. Kaluski, I. Kobrin, R. Zimlichman RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 41 2003 204 210
146. A. Louis, J.G. Cleland, S. Crabbe Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure Highlights of the Scientific Sessions of the American College of Cardiology, 2001 Eur J Heart Fail 3 2001 381 387
147. C.M. O'Connor, W.A. Gattis, K.F. Adams Jr Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol 41 2003 1452 1457
148. J.J. McMurray, J.R. Teerlink, G. Cotter Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 2007 2009 2019
149. P.R. Kalra, J.C. Moon, A.J. Coats Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85 2002 195 197
150. M. Packer, J. McMurray, B.M. Massie Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study J Card Fail 11 2005 12 20
151. F. Perez-Villa, A. Cuppoletti, V. Rossel, I. Vallejos, E. Roig Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension Clin Transplant 20 2006 239 244
152. R.A. Young, A. Ward Milrinone A preliminary review of its pharmacological properties and therapeutic use Drugs 36 1988 158 192
153. M.M. Givertz, J.M. Hare, E. Loh, D.F. Gauthier, W.S. Colucci Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension J Am Coll Cardiol 28 1996 1775 1780
154. M.S. Cuffe, R.M. Califf, K.F. Adams Jr Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 2002 1541 1547
155. M. Packer, J.R. Carver, R.J. Rodeheffer et al. Effect of oral milrinone on mortality in severe chronic heart failure The PROMISE Study Research Group N Engl J Med 325 1991 1468 1475
156. M. Metra, E. Eichhorn, W.T. Abraham Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials Eur Heart J 30 2009 3015 3026
157. S.D. Katz, K. Balidemaj, S. Homma, H. Wu, J. Wang, S. Maybaum Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure J Am Coll Cardiol 36 2000 845 851
158. J.J. Lepore, A. Maroo, N.L. Pereira Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension Am J Cardiol 90 2002 677 680
159. P.R. Forfia, M. Lee, R.S. Tunin, M. Mahmud, H.C. Champion, D.A. Kass
160. E. Takimoto, H.C. Champion, M. Li Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat Med 11 2005 214 222
161. J. Alaeddini, P.A. Uber, M.H. Park, R.L. Scott, H.O. Ventura, M.R. Mehra Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure Am J Cardiol 94 2004 1475 1477
162. M. Guazzi, M. Samaja, R. Arena, M. Vicenzi, M.D. Guazzi Long-term use of sildenafil in the therapeutic management of heart failure J Am Coll Cardiol 50 2007 2136 2144
163. M. Guazzi, G. Tumminello, F. Di Marco, M.D. Guazzi Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure Clin Pharmacol Ther 76 2004 371 378
164. J.J. Lepore, A. Maroo, L.M. Bigatello Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide Chest 127 2005 1647 1653
165. P. Botha, G. Parry, J.H. Dark, G.A. Macgowan Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition J Heart Lung Transplant 28 2009 676 682
166. F. Perez-Villa, M. Farrero, A. Sionis, A. Castel, E. Roig Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension J Heart Lung Transplant 29 2010 817 818
167. M. Maruszewski, M. Zakliczynski, R. Przybylski, E. Kucewicz-Czech, M. Zembala Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure Transplant Proc 39 2007 2850 2852
168. M. Zakliczynski, M. Maruszewski, L. Pyka Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates Transplant Proc 39 2007 2856 2858
169. A. Kulkarni, T.P. Singh, A. Sarnaik, H.L. Walters, R. Delius Sildenafil for pulmonary hypertension after heart transplantation J Heart Lung Transplant 23 2004 1441 1444
170. R.J. Tedford, A.R. Hemnes, S.D. Russell PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support Circ Heart Fail 1 2008 213 219
171. G.D. Lewis, R. Shah, K. Shahzad Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Circulation 116 2007 1555 1562
172. J.P. Stasch, P. Pacher, O.V. Evgenov Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease Circulation 123 2011 2263 2273
173. R. Frey, W. Muck, S. Unger, U. Artmeier-Brandt, G. Weimann, G. Wensing Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers J Clin Pharmacol 48 2008 926 934
174. F. Grimminger, G. Weimann, R. Frey First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Eur Respir J 33 2009 785 792
175. H.A. Ghofrani, M.M. Hoeper, M. Halank Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Eur Respir J 36 2010 792 799
176. H. Haddad, W. Elabbassi, S. Moustafa Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension ASAIO J 51 2005 456 460
177. A. Baldovinos, A. Kalangos, J. Sierra, M.J. Licker, B. Faidutti Is partially reversible pulmonary hypertension a contraindication for heart transplantation? Transplantation proceedings 32 2000 468 469
178. R.M. Adamson, W.P. Dembitsky, B.E. Jaski Left ventricular assist device support of medically unresponsive pulmonary hypertension and aortic insufficiency ASAIO J 43 1997 365 369
179. J.A. Petrofski, C.W. Hoopes, T.M. Bashore, S.D. Russell, C.A. Milano Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congential heart disease Ann Thorac Surg 75 2003 1005 1007
180. A. Al-Khaldi, P. Ergina, B. DeVarennes, K. Lachappelle, R. Cecere Left ventricular unloading in a patient with end-stage cardiomyopathy and medically unresponsive pulmonary hypertension Artif Organs 28 2004 158 160
181. N.G. Smedira, M.G. Massad, J. Navia Pulmonary hypertension is not a risk factor for RVAD use and death after left ventricular assist system support ASAIO J 42 1996 M733 M735
182. S.P. Salzberg, M.L. Lachat, K. von Harbou, G. Zund, M.I. Turina Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates Eur J Cardiothorac Surg 27 2005 222 225
183. D. Zimpfer, P. Zrunek, S. Sandner Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices Eur J Cardiothorac Surg 31 2007 698 702
184. J. Haft, W. Armstrong, D.B. Dyke Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices Circulation 116 2007 I8 I15
185. N.D. Patel, E.S. Weiss, J. Schaffer Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices Ann Thorac Surg 86 2008 832 840 discussion 832-40
186. G. Torre-Amione, R.E. Southard, M.M. Loebe Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support J Heart Lung Transplant 29 2010 195 200
187. C.T. Klodell Jr, T.E. Morey, E.B. Lobato Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices Ann Thorac Surg 83 2007 68 71 discussion 71